RxDoctor Payments Data

Gregory Mock, MD

Nephrology · Searcy, ARNPI 1942308101

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $452 of the $511 with a category attached, or 88.3%. It is spread thinly across 13 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $168 and has fallen 89.7% since, to $17 in 2025. That places this record below the midpoint for nephrology clinicians in AR, where the typical reported total is $925.

$511in general payments, 2019–2025

Across 36 payments — averaging $14.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$109
  • Amgen$98
  • Vifor Pharma, Inc.$98
  • Travere Therapeutics, Inc.$33
  • Otsuka America Pharmaceutical, Inc.$28
  • Calliditas Therapeutics US Inc.$27
  • plus $118 from 7 others

What the payments were for

  • Food & beverage$45288%
  • Education$6012%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$511 in reported general payments places this provider in the 40th percentile of 85 nephrology providers in Arkansas.

See all nephrology providers in Arkansas

Medicare billing

Part B allowed, 2024
$277,596
Medicare patients
524
Services billed
3,570

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol107$87,988
OzempicSemaglutide28$26,203
ClinolipidFat Emulsion/Olive/Soy/Phospho76$19,795
JardianceEmpagliflozin31$19,526
Sevelamer Carbonate61$10,618
EliquisApixaban14$10,387
RenvelaSevelamer Carbonate11$8,602
JanuviaSitagliptin Phosphate11$5,904
Calcitriol192$2,210
Tacrolimus16$2,062
Calcium Acetate18$1,359
Bumetanide27$1,107
Midodrine Hcl37$1,080
Febuxostat12$1,053
Albuterol Sulfate HfaAlbuterol Sulfate20$899

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$109$87,988107 claims
PfizerEliquis$20$10,38714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 85 nephrology providers in Arkansas.

Other nephrology in Searcy

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →